Progress the pre-clinical development of DNDI-6174 for the treatment of visceral leishmaniasis
current phase of drug development
updated 29 Apr 2020
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019.
Get our latest news, personal stories, research articles, and job opportunities.